Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maria A. Carrera
Observed name:
Maria Augusta Carrera
Institutions:
Hospital Universitario Fundación Jiménez Díaz,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Hospital Universitario General de Villalba,
Universidad Autónoma de Madrid
Observed institutions:
Hospital Universitario Fundación Jiménez Díaz,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Hospital Universitario General de Villalba,
Universidad Autónoma de Madrid
ORCID:
0000-0002-9460-1151
Observed ORCID:
0000-0002-9460-1151
OpenAlex ID:
A5137551712
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
2026
·
Javier Martin-Broto
, Sandra J. Strauss
, et al.
·
癌症:英文版
·
2
Supplementary Table S3 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Table S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Data from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S1 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Supplementary Figure S2 from Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
2026
·
Javier Martin-Broto
, Javier Martinez-Trufero
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
8
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type